Uterine fibroid: size does matter Mioma uterino: porque o tamanho importa

Mariana Crespo Marques¹, Vanessa Santos¹, José Silva Pereira² Hospital Professor Doutor Fernando Fonseca

Abstract

Leiomyomas are the most common benign tumors in reproductive age women. The incidence is higher in African descent women. Development and growth of fibroids is estrogen and progesterone dependent. Besides excessive menstrual bleeding, pelvic pain is also a common symptom. Doppler ultrasound (dUS) or magnetic resonance imaging (MRI) are useful for preoperative differentiation between benign and the more uncommon malignant forms. Treatment of leiomyomas depends on size, location, severity of symptoms and patient desire to preserve fertility. The authors present a case of a 16 cm subserous cervical myoma that occupied the pelvic cavity. Laparotomy was performed for tumor excision.

Keywords: Leiomyoma; Abnormal uterine bleeding; Fibroids treatment.

eiomyomas are benign monoclonal neoplasm that originate from the smooth muscle cells and fibroblasts of the myometrium. They represent the most common benign tumors in premenopausal women.1 Incidence increases with age during pre-menopausal years, with a lifetime risk > 80% in black women.² Development and growth of fibroids is estrogen and progesterone dependent. Aromatase in fibroids tissue leads to the endogenous production of estradiol and overexpression of hormonal receptors that facilitate the expanding of these tumors.1 Therefore, situations inducing prolonged exposure to high levels of estrogens and/or progesterone, such as obesity, polycystic ovarian syndrome, early menarche, or late pregnancy increase the risk of uterine fibroids.^{2,3} The rate of growth varies widely, even for a single individual.4

Most commonly, patients present with abnormal uterine bleeding. Other symptoms include abdominal distention, pelvic pain or symptoms related with pressure on adjacent organs, like bowel dysfunction or urinary symptoms. Symptoms are related to the size, location, and number of tumors. 1 Based on the International Federation of Gynecology and Obstetrics, leiomyomas may be classified in eight subtypes: 0-2, submucosal; ve differential diagnosis.3

dical experience.1

serous leiomyoma originating from the uterine cervix. The patient was a caucasian, 50 years-old, premenopausal, with no gynecological surveillance for the past 6 years. She presented with abdominal distention, pelvic pain, and dysmenorrhea for the past year. Clinical evaluation revealed a mass that occupied the entire pelvic cavity and extended into the abdominal cavity. MRI showed normal vascularization, suggesting a benign etiology. Due to the fibroid size and patient desire, an abdominal hysterectomy with bilateral adnexectomy was performed. Histopathological analysis revealed a benign leiomyoma with 16 cm and 855g of weight.

3-4, intersticial; 5-7, subserosal; and 8, extrauterine.

between benign and malignant forms. Risk factors for

malignant forms include increasing age, radiation of

the pelvis and use of tamoxifen. Assessment of tumor

vascularization by dUS or MRI is useful for preoperati-

Treatment options should be individualized, consi-

dering not only the size and location of the fibroid, but

also patient's age, pregnancy desire, symptoms, and me-

Pathological evaluation is necessary to distinguish

Cervical myomas are extremely rare, with a reported incidence <1%5. Hysterectomy remains the first line treatment in postmenopausal women as it eliminates the risk of recurrence. Management of premenopausal

The authors present a case illustrating a huge sub-

^{1.} Hospital Professor Doutor Fernando Fonseca EPE.

^{2.} Director do Serviço de Ginecologia, Hospital Prof. Doutor Fernando Fon-




FIGURE 1. Laparotomy. Normal uterus and adnexa anteriorly pointed by the surgeon.




FIGURE 2. Giant subserous myoma, originating from the cervix, adherent to the uterus and adnexa.

patients is more challenging if there is a desire for fertility preservation. Laparotomic/laparoscopic myomectomy and radical trachelectomy⁵ have been descri-

bed to treat giant cervical myomas and may be an option for younger patients.

Patient informed consent was obtained for publication.

REFERENCES

- 1. De la Cruz MS, Buchanan E.M. Uterine Fibroids: Diagnosis and Treatment. Am Fam Physician, 2017, 95(2):100-107
- 2. Pavone D, Clemenza S, Sorbi F, Fambrini M, Petraglia F. Epidemiology and Risk Factors of Uterine Fibroids, Best Pract Res Clin Obstet Gynaecol 2018, 46:3-11
- 3. Chabbert-Buffet N, Esber N, Bouchard P. Fibroid growth and medical options for treatment, Fertil. Steril; 2014, 102:630-639
- 4. Munro M, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in non-gravid women of reproductive age. Int J Gynecol Obstet, 2011, 113:3-13
- 5. Wong, Jolene et al. Novel management of a giant cervical myoma in a premenopausal patient. BMJ case reports 2017 doi:10.1136/bcr-2017-221408

CONFLICTS OF INTEREST

The authors declare that they have no conflict of interest.

ENDEREÇO PARA CORRESPONDÊNCIA

Mariana Crespo Marques E-mail: mcsmarques@gmail.com

RECEBIDO EM: 09/05/2021

ACEITE PARA PUBLICAÇÃO: 05/09/2021